Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (DWTX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2026
Reporting Period: Single event date (March 26, 2026)
Business Context: The registrant is a Delaware corporation with principal executive offices in Alpharetta, GA. The filing serves as a Regulation FD disclosure to announce the posting of a shareholder letter containing a corporate update on the company's website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure notice regarding a corporate update and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing solely references the release of a shareholder letter (Exhibit 99.1) as the material event.
Guidance, Outlook, and Risks
Management Commentary: The company posted a shareholder letter dated March 26, 2026, providing a corporate update. The specific content of this letter is furnished as Exhibit 99.1 and is not detailed within the body of this 8-K summary.
Legal Status of Information: The information in Item 7.01 and the attached shareholder letter is furnished, not "filed," for purposes of Section 18 of the Exchange Act and shall not be deemed incorporated by reference in other filings.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Shareholder Letter) for the full details of the corporate update.
- Verify the company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the trading status of Common Stock (DWTX) on the Nasdaq Capital Market.
- Note that the information in this filing is not incorporated by reference into other SEC filings.